Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States.
Flawless balance sheet and overvalued.
Share Price & News
How has Kezar Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KZR's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: KZR underperformed the US Biotechs industry which returned 1.9% over the past year.
Return vs Market: KZR underperformed the US Market which returned -13.3% over the past year.
Price Volatility Vs. Market
How volatile is Kezar Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StFranklin Berger Is The Independent Director of Kezar Life Sciences, Inc. (NASDAQ:KZR) And They Just Spent US$314k On Shares
2 months ago | Simply Wall StKezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
4 months ago | Simply Wall StHow Much Of Kezar Life Sciences, Inc. (NASDAQ:KZR) Do Insiders Own?
Is Kezar Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KZR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KZR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KZR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: KZR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KZR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KZR is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (2.5x).
How is Kezar Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KZR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KZR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KZR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if KZR's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if KZR's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KZR's Return on Equity is forecast to be high in 3 years time
How has Kezar Life Sciences performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: KZR is currently unprofitable.
Growing Profit Margin: KZR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KZR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KZR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KZR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: KZR has a negative Return on Equity (-44.96%), as it is currently unprofitable.
How is Kezar Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: KZR's short term assets ($81.1M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: KZR's short term assets ($81.1M) exceed its long term liabilities ($5.5M).
Debt to Equity History and Analysis
Debt Level: KZR is debt free.
Reducing Debt: KZR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KZR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KZR has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -43% each year.
What is Kezar Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KZR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate KZR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KZR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KZR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KZR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Fowler (47yo)
Mr. John Franklin Fowler serves as a Managing Director at Montebello Holdings, LLC. He is co-founder and Chief Executive Officer of Kezar Life Sciences. Mr. Fowler was the Chief Executive Officer at Health ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD1.80M) is about average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
|Co-Founder||no data||no data||no data|
|CFO & Secretary||2.08yrs||no data||0.046% $68.8k|
|Director of Finance & Operations||no data||no data||no data|
|Senior Vice President of Strategy & External Affairs||1.08yrs||no data||0.020% $30.0k|
Experienced Management: KZR's management team is considered experienced (3.6 years average tenure).
|Chairman of the Board||no data||US$75.69k||no data|
|Independent Director||3.33yrs||US$78.39k||0.17% $252.2k|
|Independent Director||3.42yrs||US$63.23k||1.79% $2.7m|
|Independent Director||2.5yrs||US$65.61k||no data|
|Director||0.33yr||no data||no data|
|Independent Director||2yrs||US$20.68k||no data|
Experienced Board: KZR's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: KZR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 85.9%.
Kezar Life Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Kezar Life Sciences, Inc.
- Ticker: KZR
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$151.175m
- Shares outstanding: 38.18m
- Website: https://www.kezarlifesciences.com
Number of Employees
- Kezar Life Sciences, Inc.
- 4000 Shoreline Court
- Suite 300
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|KZR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2018|
|2KZ||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2018|
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 05:01|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.